NASDAQ:KTTA Pasithea Therapeutics (KTTA) Stock Price, News & Analysis $0.70 +0.00 (+0.21%) As of 10:26 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pasithea Therapeutics Stock (NASDAQ:KTTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pasithea Therapeutics alerts:Sign Up Key Stats Today's Range$0.69▼$0.7250-Day Range$0.67▼$0.8652-Week Range$0.28▼$2.06Volume41,051 shsAverage Volume332,884 shsMarket Capitalization$17.49 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingReduce Company Overview Pasithea Therapeutics, Inc. (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways. The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders. Pasithea’s research approach centers on human-derived antibodies with tailored specificity and functionality, addressing areas of high unmet need such as severe chronic inflammatory conditions. By applying its platform to a range of targets, Pasithea seeks to advance innovative therapies toward regulatory milestones and strategic partnerships. Headquartered in Seattle, Washington, Pasithea Therapeutics maintains research and development operations in the Pacific Northwest, with teams dedicated to antibody engineering, translational science and regulatory strategy. The company is led by a management team with experience in biotechnology innovation, clinical development and commercialization, supported by a board of directors and scientific advisors drawn from leading academic and industry institutions. Pasithea continues to explore collaborations with academic centers and pharmaceutical partners to accelerate its therapeutic programs.AI Generated. May Contain Errors. Read More Pasithea Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreKTTA MarketRank™: Pasithea Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 423rd out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingReduce Consensus RatingPasithea Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.Upside PotentialPasithea Therapeutics has a consensus price target of $3.00, representing about 328.7% upside from its current price of $0.70.Amount of Analyst CoveragePasithea Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Pasithea Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pasithea Therapeutics are expected to decrease in the coming year, from ($0.76) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pasithea Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pasithea Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPasithea Therapeutics has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pasithea Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.09% of the float of Pasithea Therapeutics has been sold short.Short Interest Ratio / Days to CoverPasithea Therapeutics has a short interest ratio ("days to cover") of 0.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pasithea Therapeutics has recently increased by 17.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPasithea Therapeutics does not currently pay a dividend.Dividend GrowthPasithea Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.75 News SentimentPasithea Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Pasithea Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Pasithea Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Pasithea Therapeutics is held by insiders.Percentage Held by Institutions23.92% of the stock of Pasithea Therapeutics is held by institutions.Read more about Pasithea Therapeutics' insider trading history. Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KTTA Stock News HeadlinesQ2 EPS Estimate for Pasithea Therapeutics Lifted by AnalystMay 25 at 1:11 AM | americanbankingnews.comPasithea Therapeutics (NASDAQ:KTTA) Stock Price Down 1.3% - Here's WhyMay 19, 2026 | americanbankingnews.comMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.May 26 at 1:00 AM | Behind the Markets (Ad)Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerMay 4, 2026 | globenewswire.comIs Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?May 3, 2026 | finance.yahoo.comPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)April 20, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN ...April 1, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityApril 1, 2026 | globenewswire.comSee More Headlines KTTA Stock Analysis - Frequently Asked Questions How have KTTA shares performed this year? Pasithea Therapeutics' stock was trading at $1.29 at the beginning of 2026. Since then, KTTA shares have decreased by 45.8% and is now trading at $0.6998. How were Pasithea Therapeutics' earnings last quarter? Pasithea Therapeutics Corp. (NASDAQ:KTTA) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.33. When did Pasithea Therapeutics' stock split? Pasithea Therapeutics's stock reverse split before market open on Tuesday, January 2nd 2024.The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Pasithea Therapeutics IPO? Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at a price of $5.00-$7.00 per share. Who are Pasithea Therapeutics' major shareholders? Pasithea Therapeutics' top institutional shareholders include AdvisorShares Investments LLC (1.35%) and Renaissance Technologies LLC (0.37%). Insiders that own company stock include Tiago Marques and Simon Dumesnil. View institutional ownership trends. How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pasithea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA). Company Calendar Last Earnings5/15/2026Today5/26/2026Next Earnings (Estimated)6/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 KTTA's financial health is in the Yellow zone, according to TradeSmith. KTTA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KTTA CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees3Year Founded2020Price Target and Rating Average Price Target for Pasithea Therapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+327.8%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.44% Return on Assets-53.61% Debt Debt-to-Equity RatioN/A Current Ratio35.41 Quick Ratio11.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book0.32Miscellaneous Outstanding Shares24,940,000Free Float24,441,000Market Cap$17.49 million OptionableNot Optionable Beta0.22 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:KTTA) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredI was right about SpaceX. Now here's the part that mattersGoldman Sachs and JP Morgan have already been tied to allocations surrounding the SpaceX deal. When the bigges...The Oxford Club | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredOne algorithm, 17 years, nearly 2,000% total returnsA physicist in Dublin claims his AI algorithm has beaten the market for 17 consecutive years - with nearly 2,0...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
